NOVARTIS AG-SPONSORED ADR (NVS) Stock Price, Forecast & Analysis
USA - NYSE:NVS - US66987V1098 - ADR
NVS Key Statistics, Chart & Performance
The current stock price of NVS is 131.26 USD. In the past month the price decreased by -0.13%. In the past year, price increased by 27.36%.
NVS Latest News, Press Relases and Analysis
NVS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 46.62 | 970.39B | ||
| JNJ | JOHNSON & JOHNSON | 18.88 | 471.87B | ||
| MRK | MERCK & CO. INC. | 10.55 | 232.09B | ||
| PFE | PFIZER INC | 7.83 | 142.48B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.11 | 94.95B | ||
| ZTS | ZOETIS INC | 19.06 | 53.55B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.53 | 22.84B | ||
| VTRS | VIATRIS INC | 4.6 | 12.50B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.97 | 10.48B | ||
| CORT | CORCEPT THERAPEUTICS INC | 85.84 | 7.96B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 6.97B | ||
| LGND | LIGAND PHARMACEUTICALS | 27.55 | 3.94B |
Related stock screener links
About NVS
Company Profile
Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. The company is headquartered in Basel, Basel-Stadt and currently employs 75,883 full-time employees. The company went IPO on 2001-05-07. The firm develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The firm uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.
Company Info
NOVARTIS AG-SPONSORED ADR
Lichtstrasse 35
Basel BASEL-STADT CH 4056 CH
CEO: Vasant (Vas) Narasimhan
Employees: 75883
Phone: 41613241111
NOVARTIS AG-SPONSORED ADR / NVS FAQ
What does NOVARTIS AG-SPONSORED ADR do?
Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. The company is headquartered in Basel, Basel-Stadt and currently employs 75,883 full-time employees. The company went IPO on 2001-05-07. The firm develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The firm uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.
Can you provide the latest stock price for NOVARTIS AG-SPONSORED ADR?
The current stock price of NVS is 131.26 USD. The price decreased by -0.49% in the last trading session.
Does NOVARTIS AG-SPONSORED ADR pay dividends?
NOVARTIS AG-SPONSORED ADR (NVS) has a dividend yield of 3.43%. The yearly dividend amount is currently 3.79.
What is the ChartMill rating of NOVARTIS AG-SPONSORED ADR stock?
NVS has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 8 out of 10.
How is the valuation of NOVARTIS AG-SPONSORED ADR (NVS) based on its PE ratio?
The PE ratio for NOVARTIS AG-SPONSORED ADR (NVS) is 14.54. This is based on the reported non-GAAP earnings per share of 9.03 and the current share price of 131.26 USD.
Should I buy NVS stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on NVS.
Can you provide the market cap for NOVARTIS AG-SPONSORED ADR?
NOVARTIS AG-SPONSORED ADR (NVS) has a market capitalization of 251.86B USD. This makes NVS a Mega Cap stock.
NVS Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to NVS. When comparing the yearly performance of all stocks, NVS is one of the better performing stocks in the market, outperforming 81.06% of all stocks.
NVS Fundamental Analysis
ChartMill assigns a fundamental rating of 8 / 10 to NVS. NVS has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company.
NVS Financial Highlights
Over the last trailing twelve months NVS reported a non-GAAP Earnings per Share(EPS) of 9.03. The EPS increased by 21.33% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 25.69% | ||
| ROA | 13.42% | ||
| ROE | 32.47% | ||
| Debt/Equity | 0.55 |
NVS Forecast & Estimates
31 analysts have analysed NVS and the average price target is 132.95 USD. This implies a price increase of 1.29% is expected in the next year compared to the current price of 131.26.
For the next year, analysts expect an EPS growth of 16.95% and a revenue growth 9.97% for NVS